LGT Financial Advisors’s TG Therapeutics TGTX Stock Holding History

LGT Financial Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-275	Closed	-$8.28K	–	682
2024 Q4	$8.28K	Buy	+275	New	+$7.89K	0.02%	467

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LGT Financial Advisors's TGTX Position: Q1 2025 in Review

LGT Financial Advisors sold out of TG Therapeutics (TGTX) in Q1 2025, closing a stake of 275 shares — an estimated $8.28K sold.

LGT Financial Advisors first reported a position in TGTX in Q4 2024 and held it in 1 quarter. The position peaked at $8.28K in Q4 2024. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.

LGT Financial Advisors reported no remaining TG Therapeutics position as of Q1 2025 after selling out during the quarter.
LGT Financial Advisors sold 275 TG Therapeutics shares in Q1 2025, an estimated $8.28K.
LGT Financial Advisors first reported a position in TG Therapeutics in Q4 2024 and held it in 1 quarter.
LGT Financial Advisors's TG Therapeutics position peaked at $8.28K in Q4 2024.
376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.